PSMD10 and plasma cell myeloma: MP0250, an ankyrin repeat protein capable of neutralizing VEGF and HGF, effectively inhibits multiple myeloma-mediated osteolysis and myeloma cell invasion.1226 Meanwhile, MP0250 can effectively improve bortezomib efficacy without increasing toxicity, suggesting that MP0250 combined with cytotoxic therapy may be a promising therapeutic approach.1240 A phase II clinical evaluation of MP0250 in combination with bortezomib and dexamethasone in patients with multiple myeloma (NCT03136653) has been completed, although the result has not yet been disclosed.